Medication-Assisted Treatment (MAT)

Medication-Assisted Treatment (MAT) is the use of FDA-approved medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach to treating substance use disorders. MAT is primarily used for opioid use disorder (OUD) — addiction to heroin, fentanyl, prescription painkillers — but naltrexone is also FDA-approved for alcohol use disorder.

MAT works by acting on the same brain receptors as opioids, but in a safer, controlled way. Depending on the medication, MAT can reduce cravings, block the euphoric effects of opioids, relieve withdrawal symptoms, or normalize brain chemistry without producing a high.

The three FDA-approved medications for opioid use disorder are: buprenorphine (Suboxone, Sublocade, Zubsolv), methadone (Dolophine, Methadose), and naltrexone (Vivitrol). Each works differently and is suited to different situations.

MAT is not a crutch or a shortcut. Major studies show that MAT combined with counseling is significantly more effective than either medication alone or counseling alone. The National Academies of Sciences found that MAT reduces all-cause mortality among people with opioid use disorder by approximately 50%.

Buprenorphine is a partial opioid agonist — it activates opioid receptors in the brain but produces a much weaker effect than full opioids like heroin or fentanyl. This reduces cravings and withdrawal symptoms without producing significant euphoria at prescribed doses.

Suboxone is the most common brand name. It combines buprenorphine with naloxone (an opioid blocker) to discourage misuse. If taken as directed (dissolved under the tongue), the naloxone has minimal effect. If someone tries to inject it, the naloxone activates and causes immediate withdrawal.

Key facts about buprenorphine: It can be prescribed by any licensed healthcare provider (the old X-waiver requirement was eliminated in January 2023). It is available as sublingual film or tablet, and as a monthly injection (Sublocade). It can be prescribed in a regular doctor's office — no daily clinic visits required. It has a ceiling effect, meaning higher doses do not produce increasing euphoria, which makes overdose risk very low.

Common side effects include headache, nausea, constipation, insomnia, and sweating. Most side effects are mild and improve within the first few weeks. Cost ranges from $100 to $500 per month without insurance, but Medicaid covers buprenorphine in all 50 states, and most private insurance plans cover it under the Mental Health Parity and Addiction Equity Act.

Methadone is a full opioid agonist that has been used to treat opioid addiction since the 1960s. It is the longest-studied and most well-established MAT medication. Methadone eliminates withdrawal symptoms, reduces cravings, and blocks the effects of other opioids when taken at proper doses.

Unlike buprenorphine, methadone for opioid use disorder can only be dispensed through SAMHSA-certified Opioid Treatment Programs (OTPs), commonly called methadone clinics. In the early stages of treatment, patients must visit the clinic daily to receive their dose under observation.

Take-home privileges: As patients demonstrate stability (negative drug tests, regular attendance, no behavioral issues), they can earn take-home doses. SAMHSA updated its guidelines in 2024 to allow more flexible take-home schedules. After one year of stable treatment, patients may receive up to 28 days of take-home medication.

Cost: Methadone maintenance typically costs $4,000 to $7,000 per year at a clinic. Medicaid covers methadone maintenance in all states that have expanded Medicaid. Many clinics also accept private insurance and offer sliding-scale fees.

Side effects include sweating, constipation, sexual dysfunction, weight gain, and drowsiness. Methadone can cause dangerous interactions with alcohol, benzodiazepines, and other central nervous system depressants. Doses must be carefully managed by medical professionals.

Naltrexone is an opioid antagonist — it completely blocks opioid receptors, so if someone uses opioids while on naltrexone, they will not feel any effect. Vivitrol is the extended-release injectable form of naltrexone, given as a monthly intramuscular injection.

Key facts about Vivitrol: It is FDA-approved for both opioid use disorder and alcohol use disorder. It requires 7 to 14 days of complete opioid abstinence before starting (to avoid precipitated withdrawal). It is given once per month at a healthcare provider's office. It does not produce physical dependence — you can stop at any time without withdrawal. It has no abuse potential.

Who Vivitrol works best for: People who have completed detox and want to prevent relapse. People who do not want to take a daily medication. People on probation or parole where an opioid-free option is preferred. People with alcohol use disorder. People who have achieved initial stability and want relapse protection.

Cost: Vivitrol costs approximately $1,500 to $1,800 per injection without insurance. However, most insurance plans and Medicaid cover it. The manufacturer (Alkermes) also offers a patient assistance program for uninsured individuals through vivitrol.com.

Common side effects include injection site reactions, nausea, headache, fatigue, and liver enzyme elevations. It does not cause sedation or cognitive impairment.

While MAT is most commonly associated with opioid addiction, FDA-approved medications also exist for alcohol use disorder (AUD). Three medications are approved: naltrexone (oral Revia or injectable Vivitrol), acamprosate (Campral), and disulfiram (Antabuse).

Naltrexone for alcohol: Reduces the rewarding effects of alcohol and decreases cravings. Studies show naltrexone reduces heavy drinking days by approximately 25% compared to placebo. Available as daily oral pill or monthly Vivitrol injection.

Acamprosate (Campral): Helps restore the brain's chemical balance disrupted by chronic alcohol use. Most effective for people who have already stopped drinking and want to maintain abstinence. Taken as two pills three times daily.

Disulfiram (Antabuse): Creates an unpleasant reaction (nausea, vomiting, headache) if you drink alcohol while taking it. Works as a deterrent. Must be taken daily. Most effective in supervised settings.

Despite strong evidence, only about 2% of people with alcohol use disorder receive medication treatment. If you are struggling with alcohol, talk to your doctor about these options. Any primary care provider can prescribe all three of these medications.

SAMHSA Treatment Locator (findtreatment.gov): The most comprehensive search tool. Filter by 'medication-assisted treatment' to find buprenorphine prescribers, methadone clinics, and Vivitrol providers near you. You can also filter by payment type (Medicaid, sliding scale, free).

SAMHSA Helpline (1-800-662-4357): Free, confidential, 24/7 referral service. Tell them you are looking for MAT and they will connect you with providers in your area.

Buprenorphine provider search: Since the X-waiver requirement was eliminated in 2023, any licensed prescriber (doctor, nurse practitioner, physician assistant) can prescribe buprenorphine. Ask your primary care doctor if they can prescribe it. You can also search at samhsa.gov/medication-assisted-treatment/find-treatment/treatment-practitioner-locator.

Methadone clinics: Search SAMHSA's OTP locator at dpt2.samhsa.gov/treatment/ to find certified methadone clinics near you.

Federally Qualified Health Centers (FQHCs): Many community health centers now offer MAT on a sliding-scale fee basis. Find one at findahealthcenter.hrsa.gov.

Telehealth MAT: Following COVID-era rule changes made permanent in 2024, buprenorphine can be prescribed via telehealth for the initial visit. Companies like Bicycle Health, Groups Recover Together, and Ophelia offer telehealth MAT services, some accepting Medicaid.

Medicaid: All Medicaid programs cover at least one form of MAT medication. In Medicaid expansion states (41 states plus DC), coverage is comprehensive and includes buprenorphine, methadone, and naltrexone plus associated counseling. Many states have removed prior authorization requirements for MAT under Medicaid.

Medicare: Covers buprenorphine, naltrexone, and (as of 2020) methadone maintenance in OTPs. Part D covers oral medications; Part B covers Vivitrol injections.

Private insurance: The Mental Health Parity and Addiction Equity Act (MHPAEA) requires most private insurance plans to cover substance use disorder treatment at the same level as medical/surgical care. This includes MAT medications. If your insurance denies MAT coverage, you have the right to appeal.

No insurance: SAMHSA block grants fund state programs that provide MAT at no cost to uninsured individuals. The manufacturer of Vivitrol (Alkermes) offers a co-pay assistance program. Patient assistance programs exist for Suboxone (Indivior) and Sublocade. Many FQHCs provide MAT on a sliding scale, and some community organizations provide free MAT.

Cost comparison without insurance: Buprenorphine (generic) $100-$300/month. Brand Suboxone film $400-$600/month. Methadone clinic $300-$600/month. Vivitrol injection $1,500-$1,800/month.

One of the biggest barriers people on MAT face is finding recovery housing that allows medication-assisted treatment. Many sober living homes, halfway houses, and Oxford Houses have historically banned MAT medications, viewing them as 'not truly sober.' This is changing, but stigma persists.

Your rights: Under the Fair Housing Act and the Americans with Disabilities Act, individuals on MAT for a diagnosed substance use disorder are protected from discrimination. A sober living home that receives federal funding cannot categorically ban MAT. The Department of Justice has taken enforcement action against recovery homes that discriminate against MAT patients.

Finding MAT-friendly housing: SAMHSA's treatment locator can filter for facilities that accept MAT patients. The National Alliance for Recovery Residences (NARR) maintains a directory of certified recovery residences. Ask programs directly: 'Do you allow residents who are prescribed Suboxone, methadone, or Vivitrol by their doctor?'

If you are denied housing because of your MAT prescription: File a complaint with HUD (hud.gov/fairhousing), contact your state's fair housing agency, or reach out to the Legal Action Center (lac.org) which specializes in discrimination against people with substance use disorders.

If you are on probation or parole and need or are currently receiving MAT, you have important rights and considerations.

Legal protections: The Americans with Disabilities Act (ADA) protects people receiving MAT from discrimination, including in the criminal justice system. In 2023, the Department of Justice issued guidance confirming that courts, jails, prisons, and probation/parole programs generally cannot force individuals to discontinue prescribed MAT. Several federal court decisions (including Pesce v. Coppinger and Smith v. Aroostook County) have established that denying MAT to incarcerated or supervised individuals can violate the ADA and the Eighth Amendment.

Practical considerations: Inform your probation/parole officer that you are receiving MAT from a licensed prescriber. Carry documentation (prescription, doctor's letter) at all times. MAT medications (buprenorphine, methadone) will cause positive opioid results on standard drug tests — your prescriber should provide documentation. Some jurisdictions now train POs specifically on MAT protocols.

Drug courts: Many drug courts have updated their policies to allow MAT, especially buprenorphine and Vivitrol. However, some drug court judges still resist MAT. If your drug court prohibits your prescribed medication, consult a lawyer — this may violate federal law.

If your PO or court demands you stop MAT: Contact the Legal Action Center (lac.org), the ACLU, or a local legal aid organization. Federal law is increasingly on the side of MAT patients.

MAT is the most effective treatment available for opioid use disorder. The evidence is overwhelming and consistent across decades of research.

Key findings: Buprenorphine and methadone reduce opioid overdose deaths by approximately 50% (National Academies of Sciences, 2019). MAT reduces illicit opioid use by 33% to 60% compared to non-medication approaches. Patients on MAT are 75% less likely to die from any cause compared to those not in treatment. MAT increases treatment retention — patients stay in treatment 2 to 3 times longer with medication. MAT reduces criminal activity by 40% to 60% and reduces HIV and hepatitis C transmission.

Comparative effectiveness: Head-to-head studies show methadone and buprenorphine have similar effectiveness for most patients. Vivitrol (naltrexone) is effective for patients who complete detox, but the requirement for 7-14 days of abstinence before starting makes initiation more difficult. All three medications are significantly more effective than abstinence-only approaches.

Long-term outcomes: Many patients benefit from MAT for years or indefinitely, similar to other chronic medical conditions. There is no evidence-based reason to set arbitrary time limits on MAT. Tapering off MAT is associated with high relapse rates, but some patients do successfully transition off medication over time with medical supervision.

Myth: MAT is just replacing one drug with another. Fact: MAT medications are prescribed at stable, therapeutic doses that do not produce a high. They normalize brain chemistry, reduce cravings, and prevent withdrawal — the same way antidepressants treat depression or insulin treats diabetes. The World Health Organization, SAMHSA, NIDA, and every major medical organization disagree with this myth.

Myth: You are not really sober if you take MAT. Fact: Sobriety means freedom from the compulsion to use drugs destructively. MAT supports genuine recovery by stabilizing brain chemistry so people can participate in therapy, hold jobs, care for families, and rebuild their lives. Many 12-step groups now welcome MAT patients, and alternative recovery programs like SMART Recovery fully support MAT.

Myth: MAT is a lifetime commitment. Fact: The duration of MAT is an individual medical decision. Some people take MAT for months, others for years, and some choose to continue indefinitely. There is no shame in any timeline. Research shows that longer durations of MAT are associated with better outcomes, but the goal is always to support each person's recovery path.

Myth: MAT is only for severe addiction. Fact: MAT is appropriate for anyone with opioid use disorder, regardless of severity. Early intervention with MAT can prevent addiction from worsening.

Myth: Methadone clinics are dangerous. Fact: Methadone clinics are SAMHSA-certified, medically supervised facilities. They provide structured treatment with counseling, drug testing, and medical oversight.